FGFR1 antibodies and treatment of cancer
US9333257B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2012 |
| Grant date | May 10, 2016 |
| Priority date | — |
| Expiry date | Oct 11, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of an FGFR1 antibody in the treatment of cancer is disclosed, wherein the FGFR1 antibody binds FGFR1 at an epitope that is positioned in the FGFR1 primary amino acid sequence no more than 50 contiguous amino acids away from the C- or N-terminal of the FGFR1 heparin binding domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.